TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02954484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: see arm/group description. Lyrica manufacture site: Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule containing lactose and MCC (no active ingredients).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoricoxib
Description: Etoricoxib 120mg per oral once daily on postoperative days 1,2,3. 'Arcoxia' manufacture site: MSD International GMBH, Singapore

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: Etoricoxib 120mg per oral once daily on postoperative days 1,2,3. 'Arcoxia' manufacture site: MSD International GMBH, Singapore

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paracetamol
Description: Paracetamol 1g per oral 6hourly on postoperative days 1,2,3. Manufacture site: SM Pharmaceuticals, Malaysia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: Paracetamol 1g per oral 6hourly on postoperative days 1,2,3. Manufacture site: SM Pharmaceuticals, Malaysia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: patient-controlled analgesia intravenous morphine sulphate on postoperative days 1,2,3.~Manufacture site: Hameln Pharma Plus GMBH, Hameln, Germany

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: patient-controlled analgesia intravenous morphine sulphate on postoperative days 1,2,3.~Manufacture site: Hameln Pharma Plus GMBH, Hameln, Germany

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: Femoral block with ropivacaine 0.5% 30mls. Ropivacaine manufacture site: AstraZeneva AB, Sweden

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Femoral block with ropivacaine 0.5% 30mls. Ropivacaine manufacture site: AstraZeneva AB, Sweden
Study: NCT04298944

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Assessments
Description: Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Assessments
Description: Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular Assessments
Description: Participants will undergo the following cardiovascular assessments: 24-hour blood pressure monitoring, arterial stiffness measurements, endothelial function measurements.

Intervention type: DIAGNOSTIC_TEST
Intervention: Actigraphy
Description: Participants will wear an actigraph device for 7 days to measure participant's activity and sleep

Intervention type: DIAGNOSTIC_TEST
Intervention: Actigraphy
Description: Participants will wear an actigraph device for 7 days to measure participant's activity and sleep

Intervention type: DIAGNOSTIC_TEST
Intervention: Actigraphy
Description: Participants will wear an actigraph device for 7 days to measure participant's activity and sleep

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory assessments
Description: Participants will provide blood and urine samples for laboratory assessments.
Study: NCT00723801

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Atenolol 50mg PO QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Losartan 100mg PO QD
Study: NCT00774787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod 5% cream
Description: 1 packet (250 mg cream) 3 times per week for 4 weeks
Study: NCT05980312

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Splint Immobilization
Description: Patients will be randomized to receive a splint following their surgical procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Motion
Description: Patients will be randomized to receive no splint following their surgical procedure.
Study: NCT00633984

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Group Therapy (CBGT)
Description: The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Group Therapy (CBGT)
Description: The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-Cycloserine
Description: For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
Study: NCT04532112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biocontainment Device For Aerosol Generating Procedures (Biobox)
Description: The intervention consists of a biocontainment and aerosol evacuation device (Biobox) that will be placed around a patient prior to the airway procedure and remain in place throughout the airway procedure. The Biobox device is manufactured by National Flag and consists of a re-useable frame with a disposable, plastic torso drape. This is a new device that has not been used previously in a healthcare setting.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control for aerosol generating procedures
Description: There is no control device for the aerosol containment device. As such, intubation without a device will serve as the control/placebo arm for this trial.
Study: NCT01459406

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucose
Description: 500 ml water drink containing 40g glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose
Description: 500 ml water drink containing 40g fructose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructan
Description: 500 ml water drink containing 40g fructan

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructose and glucose
Description: 500 ml water drink containing 40g fructose and 40g glucose
Study: NCT01469676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtering group LG-6, Pall Biomedical Products
Description: In Filtering group, a Leukocyte filter (LG-6, Pall Biomedical Products) was placed on the CPB arterial line circuit, trying to filter the white blood cells.
Study: NCT03569644

Intervention type: OTHER
Group type: OTHER
Intervention: qualitative study
Description: Interviews
Study: NCT01241734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid
Description: Stage I:~Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7~Stage II:~RICE + Lenalidomide at the MTD days 1-7~Stage III:~Lenalidomide 25mg days 1-21 every 28 days
Study: NCT00097591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Administered orally
Study: NCT03393598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pre-expansion using Kiwi® VAC-6000M.
Description: The pre-expansion will be performed with Kiwi® VAC-6000M with the PalmPumpTM.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pre-expansion using Kiwi® VAC-6000M.
Description: The pre-expansion will be performed with Kiwi® VAC-6000M with the PalmPumpTM.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pre-heating using Hilotherm Calido®.
Description: The pre-heating will be performed with Hilotherm Calido®.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pre-heating using Hilotherm Calido®.
Description: The pre-heating will be performed with Hilotherm Calido®.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pre-expansion-heating
Description: Both preconditioning methods - Kiwi® VAC-6000M and additionally Hilotherm Calido® - will be applied.
Study: NCT02922036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WiSE System
Description: The WiSE System is an implantable cardiac system to provide LV pacing stimulation in conjunction with a co-implanted system that provides right ventricular stimulation.
Study: NCT03393598

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pre-expansion-heating
Description: Both preconditioning methods - Kiwi® VAC-6000M and additionally Hilotherm Calido® - will be applied.
Study: NCT01702792

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Vaccine
Description: Tumor cells obtained at the time of surgery are irradiated with 10,000 Gy and freeze fractured. Lysate at 1x107 tumor cell equivalent (TCE) will be used for vaccination with adjuvant, Montanide ISA 51 VG.
Study: NCT01271881

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PTA alone without use of the GORE VIABAHN
Description: PTA alone with no stent used
Study: NCT04601831

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Focal radiation therapy (RT)
Description: Radiation therapy for phase II:~Definitive 40-50 Gy EQD2 (i.e. 30 Gy in 5 fractions)~Hypofractionated regimen (i.e. 5 fractions in 1-2 weeks) recommended, but other fractionation schemes (10-20 fractions in 2-4 weeks) allowed.
Study: NCT03526679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days
Study: NCT02791581

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Breast Cancer Patients Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.~Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cardiac MRI
Description: Breast Cancer Patients Cardiac MRIs will be performed baseline, 3 months (for cancer patients only), and 24 months.~Non-Cancer Controls Cardiac MRIs will be performed baseline and 24 months.
Study: NCT03970278

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT03713294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV and PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study: NCT03131466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-voltage pulsed radiofrequency
Description: The manual PRF mode of the pain treatment generator will be turned on, the upper temperature limit will be set at 42°C, the PRF output voltage will be gradually increased to the highest voltage the patient can tolerate, and the patient will be treated for 360 s. After the treatment, 1.4 ml of a mixture of 0.4 mL of normal saline and 1 mL of 1% plain lidocaine will be injected through the needle of the cannula, and before the needle being removed, 0.5 mL of normal saline will be injected.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nerve block
Description: The radiofrequency generator will be set at the sensory stimulating mode, and the lowest frequency of 0.2 V will be used for 360s-sham PRF treatment, after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle. Before the needle being removed, 0.5 mL of normal saline will be injected.
Study: NCT02099929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee with Sugar
Description: 300mL of Coffee with 30g of Sugar

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coffee without Sugar
Description: 300mL of Coffee without Sugar

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decaffeinated Coffee without Sugar
Description: 300mL of Decaffeinated Coffee without Sugar

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water with Sugar
Description: 300mL of Water with 30g of Sugar

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Water without Sugar
Description: 300mL of Water without Sugar
Study: NCT01612780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XprESS Multi-Sinus Dilation Tool
Description: Sinus balloon dilation
Study: NCT03291847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fetal monitoring
Description: Maternal fetal monitoring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Naloxone
Description: Treatment for opioid use disorder
Study: NCT04011904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cross-over study
Description: Traditional Inuit Diet vs Westernized Diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cross-over study
Description: Traditional Inuit Diet vs Westernized Diet
Study: NCT01271881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface
Description: Covered stent produced by GORE VIABAHN
Study: NCT03963518

Intervention type: DRUG
Intervention: Immune checkpoint inhibitor
Description: Immune checkpoint inhibitor
Study: NCT03333005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APX001 with Standard of Care anti-fungal agent
Description: safety assessment
Study: NCT03236337

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOVI intervention
Description: MOVI-da Fit! is a multidimensional intervention that consists on: a) 4h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
Study: NCT00927017

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liquorice 66 g/day
Description: Liquorice 66 g/day for two weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liquorice 102 g/day
Description: Liquorice 102 g/day for two weeks
Study: NCT02203019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be administered for sedation in mechanically ventilated patients with sepsis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be administered for sedation in mechanically ventilated patients with sepsis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention of interest.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention of interest.
Study: NCT01103297

Intervention type: DEVICE
Group type: OTHER
Intervention: Variable Angle Distal Radius Plate ® (Surgery)
Description: Fracture reduction with distal radius plate
Study: NCT04592705

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange
Description: TPE is the process of plasmapheresis, an invasive procedure separating plasma from red blood cells using centrifuge-based devices.~Filtration involves the insertion of a central venous catheter in the internal jugular, femoral or subclavian vein after which blood is drawn from the patient's circulation and transferred to a filter that separates the plasma from blood cells. Thereafter, the plasma extracted is substituted with human albumin and/or FFP.
Study: NCT02165722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4 Pillars Toolkit
Description: Behavioral: Pillar 1: Convenient Vaccination Services (e.g. use every visit \[chronic and acute\] as an opportunity to vaccinate; use express vaccination clinics and dedicated vaccination stations; use influenza vaccination as an opportunity to vaccinate for other vaccines).~Behavioral: Pillar 2: Patient Notification (e.g. use electronic reminders and social media for vaccination reminders; use physician recommendations).~Behavioral: Pillar 3: Enhanced Office Systems (e.g. implement Standing Order Programs; use EMR prompts; add vaccination status as a vital sign when rooming).~Behavioral: Pillar 4: Motivation (e.g. establish an office Immunization Champion to track goal progress, aided by research team feedback).
Study: NCT04298944

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory assessments
Description: Participants will provide blood and urine samples for laboratory assessments.

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory assessments
Description: Participants will provide blood and urine samples for laboratory assessments.

Intervention type: BEHAVIORAL
Intervention: Emotional/ Behavioural assessments
Description: Emotional /Behavioral well being will be determined by questionnaires: Pediatrics Adverse Childhood Experiences Questionnaire (ACEs Q), Childrens Emotion Management Scale Questionnaire (CEMS) and Behavior Assessment System for Children (BASC)

Intervention type: BEHAVIORAL
Intervention: Emotional/ Behavioural assessments
Description: Emotional /Behavioral well being will be determined by questionnaires: Pediatrics Adverse Childhood Experiences Questionnaire (ACEs Q), Childrens Emotion Management Scale Questionnaire (CEMS) and Behavior Assessment System for Children (BASC)
Study: NCT05075252

Intervention type: PROCEDURE
Intervention: laparoscopic lavage
Description: This study aims to investigate the impact of laparoscopic lavage on the incidence of postoperative abscesses stratifying patients on the grade of appendicitis and peritoneal contamination.
Study: NCT02880852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.
Study: NCT03058796

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contralaterally Controlled Functional Electrical Stimulation (CCFES)
Description: The use of surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contralaterally Controlled Functional Electrical Stimulation (CCFES)
Description: The use of surface electrodes over the paretic finger and thumb extensors to deliver electrical stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove. uses surface electrodes over the paretic finger and thumb extensors to deliver stimulation with an intensity that is proportional to the degree of opening of the contralateral unimpaired hand wearing an instrumented glove.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand Therapy Video Games
Description: The use of video games with CCFES to encourage therapeutic hand movement at home
Study: NCT02841423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neuropsychological test battery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neuropsychological test battery